| Revenue Growth | Q3 sales $186M; Livmarli $133M ($100M US); Cholbam/Chenodal $52M. |
|---|---|
| Mgmt Confidence | High confidence in 2027 cash flow positivity and $4B peak potential. |
| Demand Visibility | Steady Alagille uptake; adult PFIC driving $10M-$15M quarterly revenue step-ups. |
| Margin Trends | Commercial contribution margin in high 50 percent of sales. |
| Op. Leverage | R&D at 50% of revenue; expected to continue for two quarters. |
| Pricing Power | Growth supported by weight-based dose increases and high therapy persistence. |
| Vol vs Price | Growth driven by new patient starts and weight-based dosing increases. |
| Segment Growth | Livmarli primary driver; adult PFIC patients largest growth contributor. |
| Capex & Debt | Repurchased $20M of 2029 notes; $500M cash and investments available. |
| Regulatory | Five submissions planned 1H 2027; PSC NDA timing remains first half. |
| Commentary | Transitioning from clinical-stage to a multi-product commercial powerhouse approaching $1B sales. |
| New Launches | Atabrios launched October 2026 for FOP patients ages 12 and older. |
Growth
Q3 net product sales reached $186M, with Livmarli contributing $133M, up from $133M total last year.
Outlook
Company expects to be cash flow positive in 2027 with $4B+ peak revenue potential.
Risks
Management used vague language regarding PSC regulatory alignment, calling it 'familiarity' rather than 'complete alignment.'
The company's earnings call, NASDAQ: MIRM, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Mirum Pharmaceuticals, Inc.: key numbers
- Share price
- $91.58Close, Nov 16
- Market cap
- $5.98B
- Shares outstanding
- 65.28MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Mirum Pharmaceuticals, Inc.
All →Mirum Pharmaceuticals Director Laura Brege Sells $1.33M of Stock
Laura Brege, Director, sold 14,167 shares of Mirum Pharmaceuticals, Inc. at $94.05 to $94.74 a share (average $94.21) in 2 transactions, worth $1.33M in total on Nov 11, 2026. Shares held after the trade: 15,703 (-17.2%).
- Value
- $1.33M
- Shares
- 14,167
- Average price
- $94.21
- Role
- Director
- Holding change
- -17.2%
- Trade date
- Nov 11, 2026
Mirum Pharmaceuticals Clinical Trial Data
Mirum Pharmaceuticals announced that its Phase 3 AZURE-4 study of brelovitug met its primary endpoint in patients with chronic hepatitis delta virus (HDV). The study showed that 59% of patients on the 300 mg weekly dose achieved the combined endpoint of virologic response and ALT normalization compared to 0% in the delayed-treatment arm. This data, alongside results from the AZURE-1 study, will form the basis of the company's U.S. registration package for brelovitug.
Mirum Pharmaceuticals CEO Christopher Peetz Sells $1.8M of Stock
Christopher Peetz, CEO, sold 20,000 shares of Mirum Pharmaceuticals, Inc. at $90.00 a share, worth $1.8M in total on Nov 4, 2026. Shares held after the trade: 206,637 (-8.8%).
- Value
- $1.8M
- Shares
- 20,000
- Price
- $90.00
- Role
- CEO
- Holding change
- -8.8%
- Trade date
- Nov 4, 2026
Mirum Pharmaceuticals Q3 2026 Results: Net Loss of $40.8M
Mirum Pharmaceuticals reported a significant net loss of $898.1 million for the nine months ended September 30, 2026, primarily driven by $756.2 million in acquired in-process research and development expenses. Despite the loss, net product sales grew to $521.8 million for the same period, up from $372.4 million in the prior year.
- Key figure
- Net loss $40.8M
Mirum Pharmaceuticals Financial Results
Mirum Pharmaceuticals reported Q3 2026 net product sales of $185.7 million, driven by strong performance from LIVMARLI and Bile Acid Medicines. The company increased its full-year 2026 net product sales guidance to a range of $715 million to $720 million following the FDA approval and launch of ATEBRIOZ for FOP.
“The third quarter was an important period of execution for Mirum, with the approval and launch of ATEBRIOZ and positive Phase 3 results across our late-stage rare liver portfolio. Positive results from AZURE-1 and additional data we’ll be sharing at AASLD reinforce the potential of brelovitug to become an important new treatment for chronic HDV, while EXPAND results support the potential to bring LIVMARLI to more patients living with rare cholestatic liver diseases, including biliary atresia.”
Chris Peetz, Chief Executive Officer of Mirum
Mirum Pharmaceuticals Clinical Trial Data
Mirum Pharmaceuticals announced positive results from Cohort 2 of its pivotal PROGRESS study evaluating ATEBRIOZ (zilurgisertib) in pediatric patients aged 6 to <12 with fibrodysplasia ossificans progressiva (FOP). The study met its endpoints with a significant reduction in total heterotopic ossification lesion volume and improved joint mobility compared to placebo, supporting a planned sNDA submission in the first half of 2027.